Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 10/10

vs
industry
vs
history
Cash-to-Debt No Debt
ADVM's Cash-to-Debt is ranked higher than
71% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. ADVM: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
ADVM' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.74  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.92
ADVM's Equity-to-Asset is ranked higher than
87% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. ADVM: 0.92 )
Ranked among companies with meaningful Equity-to-Asset only.
ADVM' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.3  Med: 0.93 Max: 0.97
Current: 0.92
-0.3
0.97
Interest Coverage No Debt
ADVM's Interest Coverage is ranked higher than
63% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ADVM: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ADVM' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 3
Altman Z-Score: 4.11
Beneish M-Score: -4.62
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -3682.25
ADVM's Operating Margin % is ranked lower than
91% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. ADVM: -3682.25 )
Ranked among companies with meaningful Operating Margin % only.
ADVM' s Operating Margin % Range Over the Past 10 Years
Min: -7923.3  Med: -4266.08 Max: -719.58
Current: -3682.25
-7923.3
-719.58
Net Margin % -3552.21
ADVM's Net Margin % is ranked lower than
91% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. ADVM: -3552.21 )
Ranked among companies with meaningful Net Margin % only.
ADVM' s Net Margin % Range Over the Past 10 Years
Min: -7817.66  Med: -4441.26 Max: -1099.17
Current: -3552.21
-7817.66
-1099.17
ROE % -29.38
ADVM's ROE % is ranked lower than
58% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. ADVM: -29.38 )
Ranked among companies with meaningful ROE % only.
ADVM' s ROE % Range Over the Past 10 Years
Min: -48.59  Med: -40.54 Max: -23.6
Current: -29.38
-48.59
-23.6
ROA % -27.08
ADVM's ROA % is ranked lower than
62% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. ADVM: -27.08 )
Ranked among companies with meaningful ROA % only.
ADVM' s ROA % Range Over the Past 10 Years
Min: -717.34  Med: -45.6 Max: -22.27
Current: -27.08
-717.34
-22.27
ROC (Joel Greenblatt) % -1610.22
ADVM's ROC (Joel Greenblatt) % is ranked lower than
75% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. ADVM: -1610.22 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ADVM' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -45075  Med: -4399.65 Max: -1610.22
Current: -1610.22
-45075
-1610.22
3-Year Revenue Growth Rate -32.70
ADVM's 3-Year Revenue Growth Rate is ranked lower than
99.99% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. ADVM: -32.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ADVM' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -32.7  Med: 46.1 Max: 124.9
Current: -32.7
-32.7
124.9
3-Year EBITDA Growth Rate 30.30
ADVM's 3-Year EBITDA Growth Rate is ranked lower than
99.99% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. ADVM: 30.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ADVM' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 30.3  Med: 42.5 Max: 54.7
Current: 30.3
30.3
54.7
3-Year EPS without NRI Growth Rate 29.70
ADVM's 3-Year EPS without NRI Growth Rate is ranked lower than
99.99% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. ADVM: 29.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ADVM' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 29.7  Med: 42.3 Max: 54.9
Current: 29.7
29.7
54.9
GuruFocus has detected 5 Warning Signs with Adverum Biotechnologies Inc $ADVM.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ADVM's 30-Y Financials

Financials (Next Earnings Date: 2017-11-08 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

ADVM Guru Trades in Q3 2016

Jim Simons 1,004,400 sh (+36.63%)
PRIMECAP Management 426,300 sh (+0.57%)
Chuck Royce 92,346 sh (-52.24%)
» More
Q4 2016

ADVM Guru Trades in Q4 2016

Chuck Royce Sold Out
PRIMECAP Management 425,600 sh (-0.16%)
Jim Simons 969,700 sh (-3.45%)
» More
Q1 2017

ADVM Guru Trades in Q1 2017

Jim Simons 1,141,977 sh (+17.77%)
PRIMECAP Management 440,400 sh (+3.48%)
» More
Q2 2017

ADVM Guru Trades in Q2 2017

Jim Simons 1,423,940 sh (+24.69%)
PRIMECAP Management 490,700 sh (+11.42%)
» More
» Details

Insider Trades

Latest Guru Trades with ADVM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:REPH, NAS:GNCA, NAS:TRVN, NAS:CBMG, NAS:VCEL, NAS:XOMA, NAS:BDSI, NAS:XBIT, NAS:PPHM, TSX:VBV, OTCPK:HPPI, AMEX:AST, NAS:CEMP, NYSE:KDMN, NAS:SRNE, NAS:RGLS, NAS:ALPN, NAS:ALRN, NAS:ALDX, OTCPK:ARPO » details
Traded in other countries:AVU.Germany,
Headquarter Location:USA
Adverum Biotechnologies Inc is a gene therapy company committed to discovering and developing novel medicines that can offer potentially life-changing therapeutic benefit to patients living with rare diseases or diseases of the eye.

Adverum Biotechnologies Inc is a gene therapy company. It is committed to discovering and developing novel medicines that can offer potentially life-changing therapeutic benefit to patients living with rare diseases or diseases of the eye. Adverum is focused on advancing its three lead gene therapy programs to address unmet needs in wet age-related macular degeneration and in rare diseases alpha-1 antitrypsin deficiency and hereditary angioedema. For wet age-related macular degeneration, it has two anti-VEGF gene therapy candidates, ADVM-022 and ADVM-032. The company is also advancing ADVM-043 and ADVM-053 to treat alpha-1 antitrypsin deficiency and hereditary angioedema.

Top Ranked Articles about Adverum Biotechnologies Inc

Adverum Biotechnologies Appoints Eric G. Carter, M.D., Ph.D. to Board of Directors
Adverum Biotechnologies to Present at BioCentury’s 24th Annual NewsMakers in the Biotech Industry Conference
Adverum Biotechnologies, Inc. Announces Appointment of Athena Countouriotis, M.D. as SVP and Chief Medical Officer
Adverum Biotechnologies, Inc. Announces Data Presentations at the ARVO and ASGCT 2017 Annual Meetings
Adverum Biotechnologies Reports First Quarter 2017 Financial Results and Provides Update
Adverum Biotechnologies, Inc. Appoints Richard N. Spivey, Pharm.D., Ph.D. to Board of Directors
Adverum Biotechnologies Announces Updated Presentation Time for ARM 5th Annual Cell & Gene Therapy Investor Day
Adverum Biotechnologies to Present at the ARM 5th Annual Cell & Gene Therapy Investor Day
Adverum Biotechnologies, Inc. Appoints Patrick Machado, J.D. to Board of Directors

-- Mr. Machado to Chair Audit Committee -- MENLO PARK, Calif., March 14, 2017 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a leading gene therapy company advancing novel medicines to address unmet needs in serious rare and ocular diseases, today announced the appointment of Patrick Machado, J.D. to its board of directors. Mr. Machado will be the chairman of the audit committee. “Pat is an experienced board member and executive who has led finance, business development and legal functions for two decades at biopharmaceutical companies, spanning development to commercial stage. We look forward to benefitting from his energy and extensive background,” said Paul Cleveland, executive chairman of the board of Adverum.  “Adverum has begun a new phase as a company, with a new board and executive leadership, a robust pipeline, and a platform of industry-leading technology all coming together as we advance toward becoming a clinical-stage company by the end of this year.” Mr. Machado has 20 years of experience with biopharmaceutical companies leading finance, business development, and legal functions. In addition to being a qualified financial and legal expert, he has a broad business background. Most recently, he was a co-founder of Medivation, Inc. and served as its chief business officer from 2009 to 2014, as its chief financial officer from 2004 until his retirement in 2014, and as a member of its board of directors from April 2014 until its acquisition by Pfizer in September 2016. From 1998 to 2001, Mr. Machado worked with ProDuct Health, Inc. as senior vice president, chief financial officer and earlier as general counsel. Upon ProDuct Health’s acquisition by Cytyc Corporation, he served as a consultant to Cytyc to assist with transitional matters from 2001 to 2002. Earlier in his career, Mr. Machado worked for Morrison & Foerster LLP, an international law firm, and for the Massachusetts Supreme Judicial Court. Mr. Machado received a J.D. from Harvard Law School and a B.A. and B.S. in German and Economics, respectively, from Santa Clara University. Mr. Machado also serves as a member of the board of directors at Armaron Bio, Chimerix, Inc., Inotek Pharmaceuticals Corporation, Roivant Sciences, and SCYNEXIS, Inc. At Chimerix and Inotek, Mr. Machado serves as a member of the audit committees. About Adverum Biotechnologies, Inc.
Adverum is a gene therapy company advancing novel medicines that can offer life-changing benefits to patients living with serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat wet age-related macular degeneration (wAMD) and rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE). Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, the Company generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum has collaboration agreements with Regeneron Pharmaceuticals to research, develop, and commercialize gene therapy products for ophthalmic diseases and Editas Medicine to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. Adverum’s core capabilities include clinical development and in-house manufacturing expertise, specifically in process development and assay development. For more information please visit www.adverum.com. Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding Adverum’s plans, potential opportunities, expectations, projections, goals, objectives, milestones, strategies and product pipeline, all of which are based on certain assumptions made by Adverum on current conditions, expected future developments and other factors Adverum believes are appropriate in the circumstances. Adverum may not consummate any plans or product or clinical development goals in a timely manner, or at all, or otherwise carry out the intentions or meet the expectations or projections disclosed in its forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the risk that Adverum’s resources will not be sufficient for Adverum to conduct or continue planned development programs and planned clinical trials, the risk of a delay in the enrollment of patients in Adverum’s clinical studies or in the manufacturing of products to be used in such clinical studies, and the risk that Adverum will not be able to successfully develop or commercialize any of its product candidates. Risks and uncertainties facing Adverum are described more fully in Adverum’s periodic reports filed with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Adverum undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Contacts for Adverum:

Leone Patterson
Chief Financial Officer
Adverum Biotechnologies, Inc.
650-665-7222
[email protected]

Jill Steier
Senior Vice President
The Trout Group LLC
646-378-2946
[email protected]

Read more...

Ratios

vs
industry
vs
history
PB Ratio 0.78
ADVM's PB Ratio is ranked higher than
97% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. ADVM: 0.78 )
Ranked among companies with meaningful PB Ratio only.
ADVM' s PB Ratio Range Over the Past 10 Years
Min: 0.41  Med: 0.7 Max: 8.97
Current: 0.78
0.41
8.97
PS Ratio 77.27
ADVM's PS Ratio is ranked lower than
79% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. ADVM: 77.27 )
Ranked among companies with meaningful PS Ratio only.
ADVM' s PS Ratio Range Over the Past 10 Years
Min: 34.3  Med: 71.95 Max: 1683.43
Current: 77.27
34.3
1683.43
EV-to-EBIT 0.78
ADVM's EV-to-EBIT is ranked higher than
90% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. ADVM: 0.78 )
Ranked among companies with meaningful EV-to-EBIT only.
ADVM' s EV-to-EBIT Range Over the Past 10 Years
Min: -46.5  Med: 0.8 Max: 3
Current: 0.78
-46.5
3
EV-to-EBITDA 0.80
ADVM's EV-to-EBITDA is ranked higher than
91% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. ADVM: 0.80 )
Ranked among companies with meaningful EV-to-EBITDA only.
ADVM' s EV-to-EBITDA Range Over the Past 10 Years
Min: -46.8  Med: 0.8 Max: 3.1
Current: 0.8
-46.8
3.1
EV-to-Revenue -27.75
ADVM's EV-to-Revenue is ranked lower than
99.99% of the 716 Companies
in the Global Biotechnology industry.

( Industry Median: 13.06 vs. ADVM: -27.75 )
Ranked among companies with meaningful EV-to-Revenue only.
ADVM' s EV-to-Revenue Range Over the Past 10 Years
Min: -76.5  Med: -38.6 Max: 2065.1
Current: -27.75
-76.5
2065.1
Current Ratio 24.02
ADVM's Current Ratio is ranked higher than
92% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. ADVM: 24.02 )
Ranked among companies with meaningful Current Ratio only.
ADVM' s Current Ratio Range Over the Past 10 Years
Min: 0.46  Med: 30.07 Max: 44.86
Current: 24.02
0.46
44.86
Quick Ratio 24.02
ADVM's Quick Ratio is ranked higher than
92% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. ADVM: 24.02 )
Ranked among companies with meaningful Quick Ratio only.
ADVM' s Quick Ratio Range Over the Past 10 Years
Min: 0.46  Med: 30.07 Max: 44.86
Current: 24.02
0.46
44.86

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -124.80
ADVM's 3-Year Average Share Buyback Ratio is ranked lower than
99.99% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. ADVM: -124.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ADVM' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -124.8  Med: -108.5 Max: -92.2
Current: -124.8
-124.8
-92.2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 0.81
ADVM's Price-to-Net-Cash is ranked higher than
99% of the 530 Companies
in the Global Biotechnology industry.

( Industry Median: 7.61 vs. ADVM: 0.81 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ADVM' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.58  Med: 0.82 Max: 8.36
Current: 0.81
0.58
8.36
Price-to-Net-Current-Asset-Value 0.80
ADVM's Price-to-Net-Current-Asset-Value is ranked higher than
99% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: 7.13 vs. ADVM: 0.80 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ADVM' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.58  Med: 0.81 Max: 8.31
Current: 0.8
0.58
8.31
Price-to-Tangible-Book 0.79
ADVM's Price-to-Tangible-Book is ranked higher than
98% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. ADVM: 0.79 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ADVM' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.57  Med: 0.8 Max: 8.22
Current: 0.79
0.57
8.22
Price-to-Median-PS-Value 1.07
ADVM's Price-to-Median-PS-Value is ranked higher than
64% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. ADVM: 1.07 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ADVM' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.47  Med: 1.23 Max: 21.43
Current: 1.07
0.47
21.43
Earnings Yield (Greenblatt) % 130.59
ADVM's Earnings Yield (Greenblatt) % is ranked higher than
97% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. ADVM: 130.59 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ADVM' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -1000.2  Med: 75 Max: 916.3
Current: 130.59
-1000.2
916.3

More Statistics

Revenue (TTM) (Mil) $1.81
EPS (TTM) $ -1.48
Beta2.38
Short Percentage of Float1.56%
52-Week Range $2.40 - 4.55
Shares Outstanding (Mil)43.29
» More Articles for ADVM

Headlines

Articles On GuruFocus.com
Adverum Biotechnologies Appoints Eric G. Carter, M.D., Ph.D. to Board of Directors Sep 07 2017 
Adverum Biotechnologies to Present at BioCentury’s 24th Annual NewsMakers in the Biotech Indust Sep 07 2017 
A Net Net Stock Trading at 10% of Book Aug 30 2017 
Adverum Biotechnologies, Inc. Announces Appointment of Athena Countouriotis, M.D. as SVP and Chie Jun 20 2017 
Adverum Biotechnologies, Inc. Announces Data Presentations at the ARVO and ASGCT 2017 Annual Meeting May 10 2017 
Adverum Biotechnologies Reports First Quarter 2017 Financial Results and Provides Update May 09 2017 
Adverum Biotechnologies, Inc. Appoints Richard N. Spivey, Pharm.D., Ph.D. to Board of Directors Apr 20 2017 
Adverum Biotechnologies Announces Updated Presentation Time for ARM 5th Annual Cell & Gene Therapy I Apr 17 2017 
Adverum Biotechnologies to Present at the ARM 5th Annual Cell & Gene Therapy Investor Day Apr 06 2017 
Adverum Biotechnologies, Inc. Appoints Patrick Machado, J.D. to Board of Directors Mar 14 2017 

More From Other Websites
Marinus Stock Surges on Successful Phase II Epilepsy Study Sep 12 2017
Is Adverum Biotechnologies an Incredible Momentum Stock? 3 Reasons Why ADVM Will Be Tough to Beat Sep 12 2017
Adverum Biotechnologies Appoints Eric G. Carter, M.D., Ph.D. to Board of Directors Sep 07 2017
Adverum Biotechnologies to Present at BioCentury’s 24th Annual NewsMakers in the Biotech Industry... Sep 07 2017
ETFs with exposure to Adverum Biotechnologies, Inc. : August 31, 2017 Aug 31 2017
Adverum Biotechnologies, Inc. :ADVM-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017 Aug 24 2017
Adverum Biotechnologies Reports Second Quarter 2017 Financial Results and Provides Update Aug 08 2017
What's in the Cards for Adverum (ADVM) this Earnings Season? Aug 01 2017
ETFs with exposure to Adverum Biotechnologies, Inc. : May 15, 2017 May 15 2017
Adverum Biotechnologies, Inc. :ADVM-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017 May 12 2017
Adverum Biotechnologies posts 1Q loss May 09 2017
What's in Store for Adverum (ADVM) in Q1 Earnings? May 03 2017
ETFs with exposure to Adverum Biotechnologies, Inc. : April 12, 2017 Apr 12 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}